Alnylam Pharmaceuticals (NASDAQ: ALNY) Executive Vice President and Chief R&D Officer Pushkal Garg completed a sale of 2,242 shares of common stock on February 13, 2026, according to a Form 4 filed with the Securities and Exchange Commission.
The sales were executed at a weighted average price of $310.0808 per share, yielding aggregate proceeds of $695,201. Reported execution prices ranged from $302.55 to $314.60.
The filing indicates the disposition was made to satisfy minimum statutory tax withholding obligations arising from the vesting of a performance-based stock unit - a PSU originally granted on February 27, 2023. On February 12, 2026, Alnylam issued 4,579 shares to Garg upon vesting of forty percent of the shares subject to that PSU, a vesting event triggered by Alnylam publicly reporting achievement of non-GAAP operating income for fiscal year 2025. For the issuance connected to the vesting, the price per share was recorded as $0.
Following the February 13 sale, Garg’s direct ownership stands at 24,848 shares of Alnylam common stock. He also has indirect holdings of 431 shares through a managed account and 250 shares held in trust, as reported in the filing.
Company performance and market context
Alnylam is reported to have a market capitalization of $44.14 billion and has been profitable over the last twelve months, with a reported diluted earnings per share of $2.33. A financial assessment on InvestingPro rates the company’s financial health as "GOOD," with a numeric score of 2.89. The same analysis notes expectations among analysts for net income growth this year and states the company is trading slightly above its Fair Value.
Quarterly results and analyst commentary
In its Q4 2025 earnings release, Alnylam reported an earnings per share of $1.25, which exceeded the forecast of $1.19. The company’s revenue for the quarter was $1.1 billion, falling short of the $1.15 billion that had been expected.
Analyst responses to Alnylam’s results and prospects were mixed. Freedom Capital Markets upgraded its rating on Alnylam to Buy from Hold, citing strong revenue growth of AMVUTTRA in both the U.S. and international markets as a rationale for the upgrade. RBC Capital kept an Outperform rating in place but reduced its price target to $450, citing potential short-term headwinds while also recognizing the company’s notable revenue growth in 2025. BofA Securities maintained a Buy rating and adjusted its price target to $460, pointing to upcoming catalysts such as completion of phase 2 trial enrollment for mivelsiran and the planned start of another phase 2 trial in Alzheimer’s disease.
These analyst actions reflect a mixture of optimism tied to product revenue momentum and caution about nearer-term challenges, according to the statements included in the filings and company disclosures.
What the filing explicitly shows
- Sale date: February 13, 2026.
- Shares sold: 2,242.
- Weighted average sale price: $310.0808.
- Total proceeds: $695,201.
- Price execution range: $302.55 to $314.60.
- Shares issued on vesting: 4,579 (on February 12, 2026) at $0 per share for the issuance transaction.
The Form 4 filing frames the sale as a tax-withholding action tied directly to PSU vesting and reports Garg’s remaining direct and indirect holdings in Alnylam common stock.